Publication
Breakthrough Technologies Drive Upsurge in CNS Dealmaking
IQVIA Pharma Deals
Sep 09, 2022
通过提交此表格,您同意我们的Terms of Useand隐私Policy。您提供的信息可能会收集并自动存储在我们的数据库中,可用于向您发送有关IQVIA和我们的服务的其他信息。此类信息也可以转移到其他国家 /地区的IQVIA公司。版权所有©2018-2022 IQVIA Holdings Inc.及其分支机构。版权所有。

In recent years, diseases of the central nervous system (CNS) have increasingly become more prominent in dealmaking within the life sciences sector, despite the multiple challenges faced in drug development such as high R&D costs and late-stage clinical disappointments. Notably, there was a marked increase in CNS deal volume from 2020 to 2021, with neurology drug candidates being the key drivers of several high-profile deals, particularly in relation to novel therapeutic modalities and delivery approaches.

Related solutions